{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Novel Drug Development in CLL & HNLA ((Non-Physician Credit))
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
The certificate for this activity is for NON-PHYSICIANS.Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed. While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.Purpose of Activity
To provide information on the incidence of pneumonitis in a phase-II dose-escalation study of idelalisib and entospletinib for the treatment of chronic lymphocytic leukemia (CLL) and non Hodgkin lymphoma (NHL).Learning Objectives
After completing this continuing education activity you will be able to:
Identify the implications of a study that aimed to improve the depth of remission and durability of responses in chronic lymphatic leukemia (CLL) and non-Hodgkin lymphoma (NHL) by combining idelalisib, a selective inhibitor of PI3-kinase (PI3K), with entospletinib.
Disclosures
All staff and planners, including spouses/partners (if any), in any position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.
Price:
$10.00
Credits:
- ACCME 1.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Other Health Professional
Test Code: OTN0716
Published: Jul 2016
Expires: 1/1/2026
Sources:
Oncology Times
Required Passing Score: 7/10 (70%)
Specialties:
Oncology